MERGE microbial strain improvement technique
MERGE uses non-GMO techniques to turn probiotics into therapeutics and reliable, commercial strains
MERGE is a patented strain improvement technique which used a type of directed evolution resulting in new phenotypes and antimicrobials. It turns mediocre results into repeatable and reliable results.
SciBac has used MERGE to create 2 novel lung therapeutics with multiple mechanisms designed to clear chronic lung infections in cystic fibrosis.
- Infection prevention
- Antimicrobial stewardship
- Alternative antimicrobials
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Fungi
- Yeasts
- Parasites
- Viruses
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Joint Venture
- Sell
- Outsource
Funding organisation:
Infectious disease area:
Geographic origin:
We are looking for partners to develop our lung therapeutics or to make novel ones with MERGE.
We are a pre-clinical, biotech start-up. We have raised $2M and looking for additional revenue through out-licensing as well as angel investments.
SciBac is open to improving existing biotherapeutics or creating new ones. We can use our technology to go after AMR anywhere there is a microbiome, so skin, uro-genital, lung, mouth, and gastro-intestinal applications can all be addressed.
